ClinicalTrials.gg
TerminatedNCT05917470Updated Dec 11, 2024Results posted

A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

A Phase 1/2 interventional study of ONCT-534 in Metastatic Castration-resistant Prostate Cancer, sponsored by Oncternal Therapeutics, Inc. Terminated at 10 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by Oncternal Therapeutics, Inc · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Oncternal Therapeutics, Inc. announced on 12 SEP 2024 its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen receptor inhibitor for the treatment of patients with metastatic castration resistant cancer.
Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

A first-in-human clinical trial to test the investigational treatment ONCT-534 in participants with metastatic castration-resistant prostate cancer. The main questions it aims to answer are:

  • What are the most tolerable doses of ONCT-534? (Phase 1)
  • Does ONCT-534 have anti-tumor activity at tolerable doses? (Phase 2)

This is a dose escalation and expansion study where participants will receive daily oral doses of ONCT-534.

Read the detailed description

This is a Phase 1/2 multi-center study to investigate the safety, tolerability, and anti-tumor acitivity of ONCT-534 in patients with relapsed or refractory metastatic castration-resistant prostate cancer. The study consists of 2 phases: a Phase 1 Dose Escalation and a Phase 2 Dose Expansion.

  • During the dose escalation in Phase 1 a group of participants will be assigned a certain dose level. Once the dose level is considered safe, the next group will be assigned a higher dose level. The dose level may be raised or lowered depending on any safety events that occur throughout Phase 1. There will be approximately 27 participants enrolled in Phase 1. At the end of Phase 1, two dose levels will be chosen to be tested in Phase 2.
  • During Phase 2, participants will be randomly assigned to 1 of the 2 dose levels chose in Phase 1. Approximately 16 participants will be enrolled in each of the 2 dose level groups, for a total of 32 participants.
02

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • Metastatic Prostate Cancer
03

In context

Prostatic Neoplasms

7,046 studies on the registry are indexed under Prostatic Neoplasms; 1,580 are open to participants now.

This study's enrollment of 21 is below the median of 60 across 5,348 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Oncternal Therapeutics, Inc is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is ≥18 years of age
  • Subject has documented adenocarcinoma of the prostate confirmed by without neuroendocrine differentiation or small cell features.
  • Subjects has a history of metastatic CRPC.
  • Subject has R/R disease following treatment with at least one next-generation AR-signaling inhibitor.
  • Subject has at least 1 according to (RECIST) v1.1 criteria or evaluable bony disease. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy.
  • Subject has an performance status of 0,1 or 2, and of ≥ 6 months.
  • Subject agrees to take or continue luteinizing hormone-releasing hormone agonist or antagonist therapy or has undergone bilateral orchiectomy.
  • At least 2 weeks or five half-lives have elapsed, whichever is earliest, since last systemic therapy, including taxanes or other chemotherapy. At least one month has elapsed since systemic therapy with radionuclide pharmaceutical agents
  • Subject has evidence of disease progression on or after their most recent systemic treatment
  • Subject has a PSA level ≥ 10 ng/mL, or ≥ 2 ng/mL and ≥ 50% increase from nadir on prior therapy, whichever is lowest.
  • Subject has serum testosterone \< 50 ng/dL.
  • Subject has adequate renal, hepatic, and pulmonary function
  • Subject is committed to practice true abstinence, or use a highly effective method of with any female partner of unless documented to be surgically sterile (i.e., vasectomy or bilateral orchiectomy) and to not make semen donations during the study and for 3 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Subject has small cell prostate cancer or neuroendocrine disease histology, including mixed histology.
  • Subject has to the brain or central nervous system
  • Subject is receiving concurrent anti-cancer therapy (including chemotherapy, antibody therapy, immunotherapy, cellular therapy, or other experimental therapies) except for ongoing androgen inhibiting therapy such as luteinizing hormone-releasing hormone (LHRH) agonists. Supportive non-cancer directed therapies such as bisphosphonates or denosumab are allowed.
  • Subjects taking a strong inhibitor of or a substrate of CYP2C9 or CYP2C19
  • Subject had major surgery within 30 days prior to start of study drug.
  • Subject has current, untreated pathologic long-bone fractures(s), or risk of imminent pathologic fracture(s).
  • Subject has current or imminent spinal cord compression.
  • Subject has an active seizure disorder or a history of seizure disorder(s).
  • Subject has evidence of active infection, virus (HBV), or virus (HCV)
  • Subject has any other serious illness or medical condition that would interfere with study participation
  • Subject has abnormal (ECGs) that are , including average > 450 ms, or a history of Torsade de Pointes.
  • Subject has any infection requiring parenteral antibiotic therapy or causing fever (temperature >100.5°F or 38.1°C) within 1 week prior to first dose.
  • Clinically significant other with the potential to confound study assessments, with the exception of e.g., treated cutaneous squamous cell and basal carcinomas, non-muscle invasive bladder cancer, Rai Stage 0 CLL, and adequately treated Stage 1 to 2 non-cutaneous malignancy in remission for 5 years.
  • Subject is unable to comply with the protocol and/or not willing or not available for follow-up assessments
  • Subject has any medical intervention or other condition which, in the opinion of the Investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Dose Level 1: 40mg QD

    40mg of single agent ONCT-534 to be administered daily in oral tablets

    Drug: ONCT-534

  • Experimental
    Dose Level 2: 80mg QD

    80mg of single agent ONCT-534 to be administered daily in oral tablets

    Drug: ONCT-534

  • Experimental
    Dose Level 3: 160mg QD

    160mg of single agent ONCT-534 to be administered daily in oral tablets

    Drug: ONCT-534

  • Experimental
    Dose Level 4: 300mg QD

    300mg of single agent ONCT-534 to be administered daily in oral tablets

    Drug: ONCT-534

  • Experimental
    Dose Level 5: 600mg QD

    600mg of single agent ONCT-534 to be administered daily in oral tablets

    Drug: ONCT-534

  • Experimental
    Dose Level 6: 1200 mg QD

    1200mg of single agent ONCT-534 to be administered daily in oral tablets

    Drug: ONCT-534

  • Experimental
    BID Dose Level 1: 160 mg BID

    600mg of single agent ONCT-534 to be administered daily in oral tablets

    Drug: ONCT-534

  • Experimental
    BID Dose Level 2: 300 mg BID

    300mg of single agent ONCT-534 to be administered twice daily in oral tablets

    Drug: ONCT-534

Interventions

  • DrugONCT-534

    ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.

    Also known as: GTx-534, UT-34

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities Through Study Day 28

    Incidence of DLTs through Study Day 28

    Time frame: Number of Participants with Dose Limiting Toxicities Through Study Day 28

Secondary outcomes

  1. Reduction of Prostate-Specific Antigen (PSA) by More Than 50%

    Proportion of patients who achieve at least a 50% drop in PSA from baseline (PSA50)

    Time frame: Up to 51 Weeks

07

Results

Posted Dec 11, 2024

Participant flow

Participant flow — Overall Study
MilestoneDose Level 1: 40mg QDDose Level 2: 80mg QDDose Level 3: 160mg QDDose Level 4: 300mg QDDose Level 5: 600mg QDDose Level 6: 1200 mg QDBID Dose Level 1: 160 mg BIDBID Dose Level 2: 300 mg BID
Started11433333
Safety population11433333
Dlt-evaluable pop11333333
Efficacy-evaluable population11333333
Completed00000000
Not completed11433333
Withdrew: Progressive disease11231100
Withdrew: Withdrawal by subject00100000
Withdrew: Sponsor decision00102133
Withdrew: Adverse event00000100

Outcome measures

PrimaryDose Limiting Toxicities Through Study Day 28

Incidence of DLTs through Study Day 28

Time frame:
Number of Participants with Dose Limiting Toxicities Through Study Day 28
Reported as:
Count of participants · Participants
Dose Limiting Toxicities Through Study Day 28
ParticipantsDose Level 1: 40mg QDDose Level 2: 80mg QDDose Level 3: 160mg QDDose Level 4: 300mg QDDose Level 5: 600mg QDDose Level 6: 1200 mg QDBID Dose Level 1: 160 mg BIDBID Dose Level 2: 300 mg BID
Dose Limiting Toxicities Through Study Day 2800000000
SecondaryReduction of Prostate-Specific Antigen (PSA) by More Than 50%

Proportion of patients who achieve at least a 50% drop in PSA from baseline (PSA50)

Time frame:
Up to 51 Weeks
Reported as:
Count of participants · Participants
Reduction of Prostate-Specific Antigen (PSA) by More Than 50%
ParticipantsDose Level 1: 40mg QDDose Level 2: 80mg QDDose Level 3: 160mg QDDose Level 4: 300mg QDDose Level 5: 600mg QDDose Level 6: 1200 mg QDBID Dose Level 1: 160 mg BIDBID Dose Level 2: 300 mg BID
Reduction of Prostate-Specific Antigen (PSA) by More Than 50%00000000
Post-hocNumber of Subjects With Any Post-Baseline Decrease in PSA

Any reduction in PSA after Baseline (First Day of Treatment)

Time frame:
Up to 51 Weeks
Reported as:
Count of participants · Participants
Number of Subjects With Any Post-Baseline Decrease in PSA
ParticipantsDose Level 1: 40mg QDDose Level 2: 80mg QDDose Level 3: 160mg QDDose Level 4: 300mg QDDose Level 5: 600mg QDDose Level 6: 1200 mg QDBID Dose Level 1: 160 mg BIDBID Dose Level 2: 300 mg BID
Number of Subjects With Any Post-Baseline Decrease in PSA00210200

Adverse events

Collected over Up to 51 Weeks using the Safety Population. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level 1: 40mg QD0/1 (0%)1/1 (100%)1/1 (100%)
Dose Level 2: 80mg QD0/1 (0%)0/1 (0%)0/1 (0%)
Dose Level 3: 160mg QD1/4 (25%)2/4 (50%)4/4 (100%)
Dose Level 4: 300mg QD0/3 (0%)1/3 (33.3%)3/3 (100%)
Dose Level 5: 600mg QD0/3 (0%)1/3 (33.3%)3/3 (100%)
Dose Level 6: 1200 mg QD0/3 (0%)2/3 (66.7%)3/3 (100%)
BID Dose Level 1: 160 mg BID0/3 (0%)0/3 (0%)3/3 (100%)
BID Dose Level 2: 300 mg BID0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventDose Level 1: 40mg QDDose Level 2: 80mg QDDose Level 3: 160mg QDDose Level 4: 300mg QDDose Level 5: 600mg QDDose Level 6: 1200 mg QDBID Dose Level 1: 160 mg BIDBID Dose Level 2: 300 mg BID
Back PainMusculoskeletal and connective tissue disorders1/10/10/40/31/30/30/30/3
Acute Kidney InjuryRenal and urinary disorders0/10/11/41/30/31/30/30/3
AnaemiaBlood and lymphatic system disorders0/10/10/40/30/31/30/30/3
Atypical Haemolytic Uraemic SyndromeBlood and lymphatic system disorders0/10/10/40/30/31/30/30/3
Non-cardiac Chest PainGeneral disorders0/10/10/40/30/31/30/30/3
Retinal Artery OcclusionEye disorders0/10/10/40/30/31/30/30/3
SeromaInjury, poisoning and procedural complications0/10/10/41/30/30/30/30/3
Spinal Cord CompressionNervous system disorders0/10/10/41/30/30/30/30/3
Lactic AcidosisMetabolism and nutrition disorders0/10/11/40/30/30/30/30/3
Urinary Tract ObstructionRenal and urinary disorders0/10/11/40/30/30/30/30/3
Most frequent other events
Showing 10 of 38
Most frequent other events
EventDose Level 1: 40mg QDDose Level 2: 80mg QDDose Level 3: 160mg QDDose Level 4: 300mg QDDose Level 5: 600mg QDDose Level 6: 1200 mg QDBID Dose Level 1: 160 mg BIDBID Dose Level 2: 300 mg BID
Back PainMusculoskeletal and connective tissue disorders1/10/10/41/31/30/30/30/3
FatigueGeneral disorders1/10/12/41/30/31/31/30/3
FlushingVascular disorders1/10/10/40/30/30/30/30/3
Hot FlushVascular disorders1/10/10/40/30/30/31/30/3
Lumbroscral PlexopathyNervous system disorders1/10/10/40/30/30/30/30/3
ParesthesiaNervous system disorders1/10/10/40/30/30/30/30/3
Oedema PeripheralGeneral disorders0/10/10/40/31/32/30/31/3
Decreased AppetiteMetabolism and nutrition disorders0/10/12/40/30/30/30/30/3
NauseaGastrointestinal disorders0/10/12/40/31/30/30/31/3
AnaemiaBlood and lymphatic system disorders0/10/11/41/30/30/31/30/3

Baseline characteristics

Safety Population

Age, Continuous
Age, Continuous(years)Dose Level 1: 40mg QDDose Level 2: 80mg QDDose Level 3: 160mg QDDose Level 4: 300mg QDDose Level 5: 600mg QDDose Level 6: 1200 mg QDBID Dose Level 1: 160 mg BIDBID Dose Level 2: 300 mg BIDTotal
Mean538370.3 ± 3.067.3 ± 4.570.0 ± 9.076.0 ± 5.667.7 ± 11.774.0 ± 7.269.8 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level 1: 40mg QDDose Level 2: 80mg QDDose Level 3: 160mg QDDose Level 4: 300mg QDDose Level 5: 600mg QDDose Level 6: 1200 mg QDBID Dose Level 1: 160 mg BIDBID Dose Level 2: 300 mg BIDTotal
Female000000000
Male1143333321
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Level 1: 40mg QDDose Level 2: 80mg QDDose Level 3: 160mg QDDose Level 4: 300mg QDDose Level 5: 600mg QDDose Level 6: 1200 mg QDBID Dose Level 1: 160 mg BIDBID Dose Level 2: 300 mg BIDTotal
White1142322318
Black or African American000101103
Region of Enrollment
Region of Enrollment(participants)Dose Level 1: 40mg QDDose Level 2: 80mg QDDose Level 3: 160mg QDDose Level 4: 300mg QDDose Level 5: 600mg QDDose Level 6: 1200 mg QDBID Dose Level 1: 160 mg BIDBID Dose Level 2: 300 mg BIDTotal
United States1143223218
United Kingdom000011013
08

Study locations

10 sites
  • University of California San Francisco
    San Francisco, California 94143, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • XCancer Omaha
    Omaha, Nebraska 68130, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • NEXT Oncology
    Austin, Texas 78758, United States
  • NEXT Oncology
    San Antonio, Texas 78229, United States
  • Next Virginia
    Fairfax, Virginia 22031, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
  • University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin 53792, United States
  • The Royal Marsden NHS Trust
    Sutton, Surrey SM2 5PT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05917470
Lead sponsor
Oncternal Therapeutics, Inc
Responsible party
Sponsor
First posted
Jun 23, 2023
Start date
Sep 20, 2023
Primary completion
Sep 12, 2024
Completion
Sep 12, 2024
Results posted
Dec 11, 2024
Last update
Dec 11, 2024

Study contacts

Salim Yazji, MD
study director · Oncternal Therapeutics

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion